Outlook Therapeutics Inc (NASDAQ:OTLK) President and CEO Russ Trenary and Senior Vice President of Commercial Operations Joel Prieve join Proactive’s Stephen Gunnion with details of a strategic relationship with healthcare company AmerisourceBergen.
Trenary told Proactive that Outlook Therapeutics entered the relationship in preparation for the anticipated commercial launch in the United States of its ONS-5010 treatment for wet age-related macular degeneration (AMD), pending approval by the US Food and Drug Administration (FDA).
Prieve said the agreement with AmerisourceBergen for ONS-5010 was a critical step in the next phase of its pre-commercial strategy execution.
“One of the huge advantages for us as a small company is that having this kind of a relationship with AmerisourceBergen really puts us on an equal footing with the big companies in terms of being able to have access to the entire marketplace,” Trenary added.
#ProactiveInvestors #OutlookTherapeutics #AmerisourceBergen #ONS-5010 #Nasdaq
